Related Experiment Video

Updated: Feb 26, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.9K

Cracking the code of immunotherapy resistance in small cell lung cancer: molecular insights and emerging solutions

Kostas A Papavassiliou1, Dimitrios J Stravopodis2, Vassiliki A Gogou1

  • 1First University Department of Respiratory Medicine, "Sotiria" Chest Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

American Journal of Respiratory and Critical Care Medicine
|February 25, 2026
PubMed

Insights

Small cell lung cancer (SCLC) shows modest response to immunotherapy due to complex resistance. This review explores mechanisms and clinical trials to improve SCLC immune treatment.

Area of Science:

  • Oncology
  • Immunology
  • Translational Medicine

Background:

  • Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with poor prognosis.
  • Immune checkpoint inhibitors (ICIs) offer limited survival benefits in SCLC compared to non-small cell lung cancer, despite high tumor mutational burden.
  • Understanding multifaceted resistance mechanisms is crucial for improving SCLC immunotherapy.

Purpose of the Study:

  • To critically review current understanding of SCLC immunotherapy resistance.
  • To highlight intrinsic and extrinsic factors contributing to immune escape in SCLC.
  • To provide an update on clinical trials and propose a precision immunotherapy roadmap for SCLC.

Main Methods:

  • Comprehensive literature review of SCLC immunotherapy resistance.
  • Analysis of tumor-intrinsic immune escape mechanisms (genetic drivers, MHC downregulation, epigenetic repression).
  • Evaluation of the tumor microenvironment's role and SCLC molecular subtypes' immunogenic landscapes.

Main Results:

  • SCLC resistance involves tumor-intrinsic factors and a highly immunosuppressive microenvironment.
  • Emerging SCLC molecular subtypes exhibit distinct immunogenic profiles.
  • Numerous clinical trials are investigating novel strategies to enhance SCLC immune response.

Conclusions:

  • Overcoming SCLC immunotherapy resistance requires addressing complex biological mechanisms.
  • Molecular subtyping and biomarker identification are key for personalized SCLC treatment.
  • A precision immunotherapy approach, guided by biomarkers and subtype stratification, is essential for future SCLC clinical trials.
Keywords:
epigenetic modulationimmune checkpoint inhibitorsimmunotherapy resistancemolecular subtypessmall cell lung cancer

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.2K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K